Endometrial intraepithelial neoplasia

From WikiMD's WELLNESSPEDIA

Histopathology of endometrial intraepithelial neoplasia (EIN) showing glandular crowding and atypia.

Endometrial intraepithelial neoplasia (EIN) is a precancerous condition of the endometrium, the lining of the uterus. It is characterized by an abnormal proliferation of the endometrial glands, which can lead to the development of endometrial cancer. EIN is considered a precursor lesion to endometrioid endometrial carcinoma, the most common type of endometrial cancer.

Pathophysiology[edit]

EIN arises due to genetic and hormonal factors that lead to the abnormal growth of endometrial cells. One of the key genetic alterations associated with EIN is the inactivation of the PTEN tumor suppressor gene. This inactivation results in unregulated cell proliferation and increased risk of progression to cancer.

The condition is often associated with prolonged exposure to estrogen without the counterbalancing effect of progesterone, which can occur in conditions such as polycystic ovary syndrome (PCOS), obesity, and estrogen replacement therapy without progesterone.

Diagnosis[edit]

The diagnosis of EIN is typically made through endometrial biopsy or dilation and curettage (D&C). Histopathological examination reveals glandular crowding, architectural complexity, and cytological atypia. Immunohistochemical staining for PTEN can aid in the diagnosis by demonstrating loss of PTEN expression in the affected tissue.

Treatment[edit]

Management of EIN involves addressing the underlying hormonal imbalance and may include the use of progestin therapy to counteract the effects of estrogen. In cases where there is a high risk of progression to cancer, surgical intervention such as hysterectomy may be recommended.

Prognosis[edit]

The prognosis for patients with EIN depends on the timely diagnosis and appropriate management of the condition. With effective treatment, the risk of progression to endometrial cancer can be significantly reduced.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.